Using ovality to predict nonmutagenic, orally efficacious pyridazine amides as cell specific spleen tyrosine kinase inhibitors

Journal of Medicinal Chemistry

Volumn 57, Issue 6, 2014, Pages 2683-2691

  Lucas, Matthew C ^a,c   Bhagirath, Niala ^a   Chiao, Eric ^a   Goldstein, David M ^a   Hermann, Johannes C ^a   Hsu, Pei Yuan ^a   Kirchner, Stephan ^b   Kennedy Smith, Joshua J ^a   Kuglstatter, Andreas ^a   Lukacs, Christine ^a   Menke, John ^a   Niu, Linghao ^a   Padilla, Fernando ^a   Peng, Ying ^a   Polonchuk, Liudmila ^b   Railkar, Aruna ^a   Slade, Michelle ^a   Soth, Michael ^a   Xu, Daigen ^a   Yadava, Preeti ^a   Yee, Calvin ^a   Zhou, Mingyan ^a   Liao, Cheng ^a   more..

^a HOFFMANN LA ROCHE INC   (United States)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c CUBIST PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN KINASE SYK INHIBITOR; PYRIDAZINE AMIDE DERIVATIVE; PYRIDAZINE DERIVATIVE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG STRUCTURE; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN;

AMIDES; ANIMALS; COMPUTATIONAL BIOLOGY; COMPUTER SIMULATION; DRUG DESIGN; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; MICE; MICROSOMES, LIVER; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MUTAGENESIS; MUTAGENICITY TESTS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIDAZINES; RATS; SPLEEN; STRUCTURE-ACTIVITY RELATIONSHIP; X-RAY DIFFRACTION;

EID: 84897453194     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401982j     Document Type: Article

References (23)

1. Mocsai, A.; Ruland, J.; Tybulewicz, V. L. J. The SYK tyrosine kinase: A crucial player in diverse biological functions Nat. Rev. Immunol. 2010, 10, 387-402
2. Bajpai, M.; Chopra, P.; Dastidar, S. G.; Ray, A. Spleen tyrosine kinase: A novel target for therapeutic intervention of rheumatoid arthritis Expert Opin. Invest. Drugs 2008, 17, 641-659
3. Zou, W.; Kitaura, H.; Reeve, J.; Long, F.; Tybulewicz, V. L.; Shattil, S. J.; Ginsberg, M. H.; Ross, F. P.; Teitelbaum, S. L. Syk, c-Src, the αvβ3 integrin, and ITAM immunoreceptors, in concert, regulate osteoclastic bone resorption J. Cell Biol. 2007, 176, 877-888
4. Koga, T.; Inui, M.; Inoue, K.; Kim, S.; Suematsu, A.; Kobayashi, E.; Iwata, T.; Ohnishi, H.; Matozaki, T.; Kodama, T.; Taniguchi, T.; Takayanagi, H.; Takai, T. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis Nature 2004, 428, 758-763
5. Tam, F. W. K.; McAdoo, S. P. Fostamatinib disodium Drugs Future 2011, 36, 273-280
6. Pandey, A. Discovery of PRT062607: A potent and selective Syk inhibitor for the treatment of inflammatory, B cell proliferative diseases and thrombosis. CHI 6th Annual Drug Discovery Chemistry Conference, San Diego, CA, April 12-13, 2011.
7. Coffey, G.; DeGuzman, F.; Inagaki, M.; Pak, Y.; Delaney, S. M.; Ives, D.; Betz, A.; Jia, Z. J.; Pandey, A.; Baker, D.; Hollenbach, S. J.; Phillips, D. R.; Sinha, U. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis J. Pharmacol. Exp. Ther. 2012, 34, 350-359
8. Gilead. Pipeline. http://www.gilead.com/pipeline (accessed February 2014).
9. Liddle, J.; Atkinson, F. L.; Barker, M. D.; Carter, P. S.; Curtis, N. R.; Davis, R. P.; Douault, C.; Dickson, M. C.; Elwes, D.; Garton, N. S.; Gray, M.; Hayhow, T. G.; Hobbs, C. I.; Jones, E.; Leach, S.; Leavens, K.; Lewis, H. D.; McCleary, S.; Neu, M.; Patel, V. K.; Preston, A. G. S.; Ramirez-Molina, C.; Shipley, T. J.; Skone, P. A.; Smithers, N.; Somers, D. O.; Walker, A. L.; Watson, R. J.; Weingarten, G. G. Discovery of GSK143, a highly potent, selective and orally efficacious spleen tyrosine kinase inhibitor Bioorg. Med. Chem. Lett. 2011, 21, 6188-6194
10. Clemens, G. R.; Schroeder, R. E.; Magness, S. H.; Weaver, E. V.; Lech, J. W.; Taylor, V. C.; Masuda, E. S.; Baluom, M.; Grossbard, E. B. Developmental toxicity associated with receptor tyrosine kinase Ret inhibition in reproductive toxicity testing Birth Defects Res., Part A 2009, 85, 130-136
11. Friedberg, J. W.; Sharman, J.; Sweetenham, J.; Johnston, P. B.; Vose, J. M.; Lacasce, A.; Schaefer-Cutillo, J.; De Vos, S.; Sinha, R.; Leonard, J. P.; Cripe, L. D.; Gregory, S. A.; Sterba, M. P.; Lowe, A. M.; Levy, R.; Shipp, M. A. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia Blood 2010, 115, 2578-2585
12. Weinblatt, M. E.; Kavanaugh, A.; Burgos-Vargas, R.; Dikranian, A. H.; Medrano-Ramirez, G.; Morales-Torres, J. L.; Murphy, F. T.; Musser, T. K.; Straniero, N.; Vicente-Gonzales, A. V.; Grossbard, E. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial Arthritis Rheum. 2008, 58, 3309-3318
13. Lucas, M. C.; Goldstein, D.; Hermann, J. C.; Kuglstatter, A.; Liao, C.; Liu, W.; Luk, K.-C.; Padilla, F.; Wanner, J.; Xie, W.; Zhang, J. A hypothesis for the rational design of highly selective spleen tyrosine kinase inhibitors J. Med. Chem. 2012, 55, 10414
14. Padilla, F.; Bhagirath, N.; Chen, S.; Chiao, E.; Goldstein, D. M.; Hermann, J. C.; Hsu, J.; Kennedy-Smith, J. J.; Kuglstatter, A.; Liao, C.; Liu, W.; Lowrie, L. E., Jr; Luk, K.-C.; Lynch, S. M.; Menke, J.; Niu, L.; Owens, T.; O-Yang, C.; Railkar, A.; Schoenfeld, R. C.; Slade, M.; Steiner, S.; Tan, Y.-C.; Villaseñor, A. G.; Wang, Ce.; Wanner, J.; Xie, W.; Xu, D.; Zhang, X.; Zhou, M.; Lucas, M. C. Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors J. Med. Chem. 2013, 56, 1677
15. Liao, C.; Hsu, J.; Kim, Y.; Hu, D.-Q.; Xu, D.; Zhang, J.; Pashine, A.; Menke, J.; Whittard, T.; Romero, N.; Truitt, T.; Slade, M.; Lukacs, C.; Hermann, J.; Zhou, M.; Lucas, M.; Narula, S.; DeMartino, J.; Tan, S.-L. Arthritis Res. Ther. 2013, 15, R146
16. Maron, D. M.; Ames, B. N. Revised methods for the Salmonella mutagenicity test Mutat. Res. 1983, 113, 173-215
17. Villaseñor, A. G.; Kondru, R.; Ho, H.; Wang, S.; Papp, E.; Shaw, D.; Barnett, J. W.; Browner, M. F.; Kuglstatter, A. Structural insights for design of potent spleen tyrosine kinase inhibitors from crystallographic analysis of three inhibitor complexes Chem. Biol. Drug Des. 2009, 73, 466-470
18. Zimmer, D.; Mazurek, J.; Petzold, G.; Bhuyan, B. K. Bacterial mutagenicity and mammalian cell DNA damage by several substituted anilines Mutat. Res. 1980, 77, 317-326
19. Alex, A.; Millan, D. S.; Perez, M.; Wakenhut, F.; Whitlock, G. A. Intramolecular hydrogen bonding to improve membrane permeability and absorption in beyond rule of five chemical space Med. Chem. Commun. 2011, 2, 669-674
20. Waring, M. J. Lipophilicity in drug discovery Expert Opin. Drug Discovery 2010, 5, 235-248
21. Beckford, S. J.; Dixon, D. W. Molecular dynamics of anthraquinone DNA intercalators with polyethylene glycol side chains J. Biomol. Struct. Dyn. 2012, 29, 1065-1080
22. Hann, M. M.; Keserü, G. M. Finding the sweet spot: The role of nature and nurture in medicinal chemistry Nat. Rev. Drug Discovery 2012, 11, 355-364
23. Xu, D.; Kim, Y.; Postelnek, J.; Vu, M. D.; Hu, D. Q.; Liao, C.; Bradshaw, M.; Hsu, J.; Zhang, J.; Pashine, A.; Srinivasan, D.; Woods, J.; Levin, A.; O'Mahony, A.; Owens, T. D.; Lou, Y.; Hill, R. J.; Narula, S.; DeMartino, J.; Fine, J. S. RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents J. Pharmacol. Exp. Ther. 2012, 341, 90-103